Many of us at the end of a weekly lupus clinic are tempted to reflect that almost all shades of connective tissue 'overlap' occur, and that it is perhaps pointless to attempt too precise a definition in individual cases. The introduction of the concept of overlap syndromes was a pragmatic way to resolve an imprecise compromise. It represented an attempt to categorise various groups of disorders having in common some clinical and serological features, but failing to fulfil the established or proposed criteria for the classification of a distinct and separate entity, such as rheumatoid arthritis, progressive systemic sclerosis, systemic lupus erythematosus, or dermatomyositis. Some claim that as many as 25% of patients with connective tissue disease fall into one or other overlap group. 1-5
In the past few years there has been limited success with attempts to describe distinct clinical entities, generally using serological markers. These include polemic entities such as mixed connective tissue disease,6'0 subacute cutaneous lupus erythematosus," 12 or the recently described 'primary' antiphospholipid syndrome, 1--6 among others.
Following the observation by Sharp et al6 that an overlap syndrome consisting of Raynaud's phenomenon, swollen hands, arthritis, and myositis was strongly associated with the presence of antibodies to nuclear ribonucleoprotein (RNP), the concept of mixed connective tissue disease has been useful. The serological specificity of these antibodies has been defined to epitopes on a 68 kD phosphoprotein uniquely associated with the RNP containing uridylic acid-rich small nuclear RNA (U-snRNP). At least 12 U-snRNPs have been identified, which account for about 1% of the total cellular RNA. The Ul to U6-snRNPs, with the exception of U3-snRNP, are known to play an important part in messenger RNA processing. In addition, a number of core DNAs coding for these antigens have been cloned and some specific characteristics of the deduced amino acid sequences are known. '7 As the years go by clinical perception of mixed connective tissue disease has evolved considerably. For 29 In addition, it has been seen that the pattern of this disease often changes to one of progressive systemic sclerosis. Interestingly, in such patients, it is common to see a gradual reduction of the hyperglobulinaemia and disappearance of the antibodies to U-snRNP.' Finally, there have been no major advances in identifying the aetiopathogenesis of this condition or in explaining the apparent association with antibodies to U-snRNP. 29 This has led to a protracted debate about the specificity or otherwise of mixed connective tissue disease. 24 The title subacute cutaneous lupus erythematosus has been given to an overlap syndrome whose main clinical feature is the appearance of florid cutaneous lesions, often extremely photosensitive, sometimes with a characteristic serpiginous border. This disorder may include other systemic features such as Sjogren's syndrome, pericarditis, arthritis, and the occasional case of congenital heart block in the offspring (neonatal lupus). The It was obvious from the beginning that the occurrence of these overlap entities varied considerably from one centre to another. The reasons for these discrepancies may be multiple. Firstly, the clinical definitions of the major components of these syndromes-Raynaud's phenomenon, Sjogren's syndrome, myositis, lung disease, cutaneous rash, or thrombosis-are open to widely differing interpretation as well as to variation within individual patients over time. Secondly, the proposed serological 'markers'-anti-U-snRNP, anti-SSA/Ro, or antiphospholipid antibodies-are not specific for these syndromes and may be present in a variety of other autoimmune diseases. 36 Clearly, the two reasons for attempts at subdivision concern treatment and prognosis. 
